Northern Trust Corp Increases Stock Position in GSK PLC Sponsored ADR $GSK

Key Points

• Northern Trust Corp increased its stake in GSK PLC by 5.1%, purchasing an additional 105,629 shares during the first quarter, bringing its total holdings to approximately 2.17 million shares valued at $83.9 million.
• GSK reported earnings of $1.23 per share for the latest quarter, surpassing analyst expectations by $0.11, and achieved a revenue of $10.64 billion, significantly exceeding estimates of $7.92 billion.
• The company has set a dividend yield of 4.2% with a quarterly dividend of $0.4206 per share, despite maintaining a dividend payout ratio of 77.78%.

Northern Trust Corp boosted its stake in shares of GSK PLC Sponsored ADR (NYSE:GSK - Free Report) by 5.1% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The firm owned 2,165,884 shares of the pharmaceutical company's stock after buying an additional 105,629 shares during the quarter. Northern Trust Corp owned approximately 0.10% of GSK worth $83,906,000 as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in GSK. Brighton Jones LLC bought a new position in GSK during the fourth quarter valued at about $528,000. Barclays PLC grew its position in GSK by 84.2% during the fourth quarter. Barclays PLC now owns 49,628 shares of the pharmaceutical company's stock valued at $1,678,000 after buying an additional 22,689 shares during the period. Dimensional Fund Advisors LP grew its position in GSK by 0.7% during the fourth quarter. Dimensional Fund Advisors LP now owns 2,598,570 shares of the pharmaceutical company's stock valued at $87,884,000 after buying an additional 18,492 shares during the period. MGO One Seven LLC grew its position in GSK by 17.5% during the fourth quarter. MGO One Seven LLC now owns 13,436 shares of the pharmaceutical company's stock valued at $454,000 after buying an additional 1,997 shares during the period. Finally, Integrated Wealth Concepts LLC grew its position in GSK by 3.7% during the fourth quarter. Integrated Wealth Concepts LLC now owns 17,633 shares of the pharmaceutical company's stock valued at $596,000 after buying an additional 627 shares during the period. Institutional investors own 15.74% of the company's stock.

Analyst Ratings Changes

GSK has been the subject of several research reports. Wall Street Zen upgraded shares of GSK from a "hold" rating to a "buy" rating in a research report on Sunday, August 3rd. Berenberg Bank reiterated a "hold" rating on shares of GSK in a research report on Tuesday, June 3rd. Six equities research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Reduce" and a consensus target price of $37.38.

GSK Price Performance

Shares of GSK stock traded up $0.24 on Friday, reaching $39.68. The stock had a trading volume of 3,590,956 shares, compared to its average volume of 3,181,567. GSK PLC Sponsored ADR has a 1 year low of $31.72 and a 1 year high of $44.26. The company has a market cap of $80.82 billion, a P/E ratio of 18.37, a price-to-earnings-growth ratio of 1.72 and a beta of 0.51. The company has a current ratio of 0.87, a quick ratio of 0.57 and a debt-to-equity ratio of 1.07. The business's 50 day moving average is $38.40 and its two-hundred day moving average is $38.24.

GSK (NYSE:GSK - Get Free Report) last announced its quarterly earnings results on Wednesday, July 30th. The pharmaceutical company reported $1.23 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.12 by $0.11. The firm had revenue of $10.64 billion for the quarter, compared to the consensus estimate of $7.92 billion. GSK had a net margin of 10.81% and a return on equity of 49.22%. The company's revenue for the quarter was up 1.3% on a year-over-year basis. During the same period in the prior year, the firm posted $0.43 earnings per share. GSK has set its FY 2025 guidance at 4.590-4.590 EPS. As a group, research analysts anticipate that GSK PLC Sponsored ADR will post 4.14 EPS for the current year.

GSK Cuts Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, October 9th. Investors of record on Friday, August 15th will be paid a $0.4206 dividend. This represents a $1.68 dividend on an annualized basis and a yield of 4.2%. The ex-dividend date of this dividend is Friday, August 15th. GSK's dividend payout ratio (DPR) is currently 77.78%.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.